华西口腔医学杂志

• 临床研究 • 上一篇    下一篇

口腔颌面部恶性肿瘤患者血清中透明质酸含量的检测

邢汝东1,常世民2,段玉芹3,张方明2,董福生4   

  1. 1.首都医科大学北京口腔医院 颌面外科,北京100050;2.北京友谊医院 口腔科,北京100050; 3.河北医科大学第四医院 口腔科,河北 石家庄050011; 4.河北医科大学口腔医院 颌面外科,河北 石家庄050017
  • 收稿日期:2004-08-25 修回日期:2004-08-25 出版日期:2004-08-20 发布日期:2004-08-20
  • 通讯作者: 邢汝东,Tel:010-67099155
  • 作者简介:邢汝东(1958-),男,河北人,教授,硕士

Examination of Serum Hyaluronic Acid Level in Patients with Oral and Maxillofacial Malignancy

XING Ru-dong1, CHANG Shi-min2,DUAN Yu-qin3,ZHANG Fang-ming2,DONG Fu-sheng4   

  1. 1.DentalHospital,Capital University ofMedical Science,Beijing100050,China; 2.Dept.ofStomatology,BeijingFriendshipHospital,Beijing100050,China; 3.Dept.OfSto- matology,the FourthHospital,Hebei Medical University,Shijiazhuang050011,China; 4.DentalHospital,Hebei Medical Uni- versity,Shijiazhuang050017,China
  • Received:2004-08-25 Revised:2004-08-25 Online:2004-08-20 Published:2004-08-20

摘要:

目的 检测口腔颌面部恶性肿瘤患者血清中透明质酸(HA)的含量,探讨HA对口腔颌面部恶性肿瘤辅助诊断和治疗效果监测的价值。方法 选择住院治疗的口腔颌面部恶性肿瘤患者44例,健康人24例。肿瘤患者于手术前或化疗开始前采血,其中20例患者于手术后或化疗结束后再次采血;24例健康人于常规体检时采血。用放射免疫试验测定所有标本血清中的HA浓度。结果 治疗前口腔颌面部恶性肿瘤患者血清中HA含量显著高于健康人(P<0·05),口腔颌面部鳞癌患者血清中HA含量显著高于健康人(P<0·05),涎腺腺样囊性癌患者血清中HA 含量与健康人无显著差异(P>0·05)。口腔颌面部恶性肿瘤Ⅲ、Ⅳ期患者血清中HA含量显著高于Ⅰ、Ⅱ期患者和健康人(P<0·05)。口腔颌面部恶性肿瘤患者治疗后血清中HA含量低于治疗前,但差异不显著(P>0·05)。结论 HA含量测定对口腔颌面部恶性肿瘤可能有辅助诊断价值。血清中HA的含量变化可作为肿瘤分期和判断肿瘤预后的参考,但不能用于治疗效果的监测。

关键词: 口腔颌面部恶性肿瘤, 透明质酸, 放射免疫试验

Abstract:

Objective To determine the level of hyaluronic acid (HA) in serum of patients with oral and maxillofacial malig- nancy and to investigate the correlation between the levels of serumHA and stage of the malignant lesions and treatment response. Methods 44 patientswith oral and maxillofacial malignancywere analyzed and 24 healthy individuals served as controls. Venous blood was collected fromthe patients before treatment and the healthy individuals. One week aftertherapy, venous bloodwere col- lected in 24 patients once again. Serum levels ofHAwere measured with quantitative radioimmunoassay (RIA).Results Before treatment, the serumHA concentration in patients with oral and maxillofacial malignancy was significantly higher than that of the controls(P<0.05). Also, the serumHA concentration in patientswith OSCCwas significantly higher than that of the controls(P <0.05). No difference was noted in serum HA concentration between patients with salivary ACC and the control group (P> 0·05). The serumHA concentration of patients in stageⅢandⅣwas significantly higherthan that of patients in stageⅠandⅡ (P<0·05). SerumHAlevels decreased in patients after a complete treatment, butthe differencewas not significant(P>0·05). Conclusion Serum levels of HAmay be useful in diagnosis of OSCC and was associated with clinical stages in patients with oral and maxillofacial malignancy. However, it may not be contributory to monitoring treatment response in patientswith oral and max- illofacial malignancy.

Key words: oral and maxillofacial malignancy, hyaluronic acid, radioimmunoassay